- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01154049
Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis
August 9, 2016 updated by: Oswaldo Cruz Foundation
Phase 1 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis
This is a phase I, open-label, single arm trial, which aims to assess the safety of the vaccine prepared sm14 in healthy subjects.
The product immunogenicity will be evaluated by conducting serology (anti-sm14 antibodies) and testing of cellular response to the antigen by the method ELI-SPOT.
Each participant will remain in the study for approximately 4 months.
The total study duration is 10 months, considering a period of 6 months for inclusion.
Will be included in the study subjects male and female, between 18 and 49 years, that manifest their will to participate in the research by signing an Informed Consent Form.
Eligible population for the study are subjects who do not present at screening significant changes in renal, cardiac and liver functions, complete blood count, clotting, present no acute or chronic illnesses, are not in the chronic use of any medication, do not have HIV infection or other immunodeficiency.
Pregnant or breastfeeding women will not be included.
Volunteers will receive three doses of vaccine prepared sm14, in doses containing 50 mcg of the antigen, associated with adjuvant GLA-SE at a dose of 10 mcg, with an interval of 30 days between each application.
Twenty volunteers will be included in the study.
This is a convenience sample, established for the first test of the product in humans, for the initial safety assessment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Rio de Janeiro, Brazil, 21040900
- Instituto de Pesquisa Clinica Evandro Chagas (IPEC) - Fiocruz
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 49 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged between 18 and 49 years.
- Available for follow-up throughout the study period (approximately 120 days).
- Ability to understand and sign the informed consent form (IC).
- HIV serology negative
- Absence of helminth infections in general (nematodes, cestodes and trematodes, among which Schistosoma mansoni) at the inclusion in the study.
- Patients who has not chronic use or have not used in the past 45 days any medication, except trifling as nasal saline and vitamins.
- Be in good health without significant medical history.
- Screening physical examination without clinical significant abnormalities.
- Screening laboratory tests without significant abnormalities according to normal standards and the evaluation of investigators.
- Additional criteria for females of childbearing potential: Negative pregnancy test at screening; consistent use of contraceptive methods (male or female condom, diaphragm, IUD and oral contraceptives or "patches").
Exclusion Criteria:
- Women who are pregnant or breastfeeding.
- Use of cytotoxic or immunosuppressive drugs in the last six months, except for spray nasal corticosteroids for allergic rhinitis or topical corticosteroids for uncomplicated dermatitis.
- Immunoglobulin use 60 days prior to vaccination.
- Use of any type of vaccine 30 days prior to vaccination.
- Plan to receive any other vaccine during the period of participation in the study (four months)
- Use any type of investigational medication in a period of 30 days prior to vaccination
- Use of allergy shots with antigens within 14 days prior to vaccination.
- Psychiatric illness that hinders adherence to the protocol, such as psychosis, obsessive-compulsive neurosis, bipolar disorder treatment, diseases that require treatment with lithium, and suicide thoughts in the last 5 years prior to inclusion.
- Presence of neurological disease, liver disease or kidney disease (diseases which have led to hospitalization or prolonged treatment).
- History of sickle cell anemia.
- Asplenia (no spleen or its removal).
- History of alcohol use/abuse (CAGE criterion) or illicit drugs.
- Blood pressure above 140/90 mmHg at screening or hypertension requiring drug treatment.
- Coagulopathy diagnosed by a doctor or report of capillary fragility (eg, bruising, bleeding, etc.) after injections or blood sampling.
- Active malignancy (eg, any type of cancer) or treated so it may relapse during the study.
- History of allergy to vaccines containing adjuvants composed of lipids (GLA or MPL)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single arm
3 doses of the vaccine, on days 0, 30 and 60.
|
Healthy adults will receive 3 doses of the vaccine, on days 0, 30 and 60.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of the vaccine
Time Frame: 4 months after the first dose
|
Safety and tolerability of the vaccine (sm14 antigen plus GLA adjuvant) against schistosomiasis in health adults
|
4 months after the first dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of seroconversion
Time Frame: 30 days after the third vaccine dose
|
Proportion of seroconversion for sm14 antigen 30 days after the complete vaccinal schedule (3 doses, 30 days apart)
|
30 days after the third vaccine dose
|
Cellular immune response to sm-14 vaccination in health adults
Time Frame: 30 days after the third vaccine dose
|
Determine the cellular immune responses and their correlation to the development and magnitude of humoral responses
|
30 days after the third vaccine dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Marilia S Oliveira, MD, MsC, Instituto de Pesquisa Clinica Evandro Chagas (IPEC)
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2011
Primary Completion (Actual)
April 1, 2014
Study Completion (Actual)
April 1, 2014
Study Registration Dates
First Submitted
June 29, 2010
First Submitted That Met QC Criteria
June 29, 2010
First Posted (Estimate)
June 30, 2010
Study Record Updates
Last Update Posted (Estimate)
August 10, 2016
Last Update Submitted That Met QC Criteria
August 9, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- sm14-CT001P1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schistosomiasis
-
Oswaldo Cruz FoundationRecruitingVaccination; Infection | Schistosomiasis Mansoni | Schistosomiasis HaematobiumSenegal
-
Rhode Island HospitalLondon School of Hygiene and Tropical Medicine; Medical Research Council; University... and other collaboratorsRecruitingSchistosomiasis | Schistosomiasis Mansoni | Schistosoma Japonicum InfectionUganda, United Kingdom
-
Leiden University Medical CenterCompletedSchistosomiasis | Schistosomiasis MansoniNetherlands
-
Enaiblers ABMinistry of Health, Uganda; Jimma University; Ghent University, BelgiumNot yet recruitingSchistosomiasis Mansoni | Soil Transmitted Helminths
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
Oswaldo Cruz FoundationUniversidade Federal de Pernambuco; World Health OrganizationCompletedSchistosomiasis Mansoni
-
IRCCS Sacro Cuore Don Calabria di NegrarActive, not recruiting
-
Makerere UniversityUniversity of CopenhagenCompleted
-
Makerere UniversityUniversity of CopenhagenUnknown
Clinical Trials on sm14 antigen plus adjuvant GLA
-
Oswaldo Cruz FoundationRecruitingVaccination; Infection | Schistosomiasis Mansoni | Schistosomiasis HaematobiumSenegal
-
Oswaldo Cruz FoundationIDRI; Biomedical Research Center EPLS; Orygen Biotecnologia SACompleted
-
Oswaldo Cruz FoundationIDRI; Biomedical Research Center EPLS; Orygen Biotecnologia SACompletedSchistosomiasisSenegal
-
Mayo ClinicNational Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin MelanomaUnited States
-
Butantan InstituteCompletedInfluenza | H7N9 InfluenzaBrazil
-
HIV Vaccine Trials NetworkNational Institute of Allergy and Infectious Diseases (NIAID)Active, not recruiting
-
Statens Serum InstitutCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue SarcomaUnited States
-
NovavaxCompleted